×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VRTX – vertex pharmaceuticals incorporated (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VRTX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/6
06:36 am
vrtx
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
Medium
Report
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
2/6
03:08 am
vrtx
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release [Yahoo! Finance]
Medium
Report
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release [Yahoo! Finance]
2/4
08:17 am
vrtx
Jupiter Endovascular Announces Completion of Enrollment in SPIRARE II Pivotal Trial [Yahoo! Finance]
Low
Report
Jupiter Endovascular Announces Completion of Enrollment in SPIRARE II Pivotal Trial [Yahoo! Finance]
2/3
07:06 pm
vrtx
Here's How Much a $1000 Investment in Vertex Pharmaceuticals Made 10 Years Ago Would Be Worth Today [Yahoo! Finance]
Low
Report
Here's How Much a $1000 Investment in Vertex Pharmaceuticals Made 10 Years Ago Would Be Worth Today [Yahoo! Finance]
2/2
10:29 pm
vrtx
WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager [Yahoo! Finance]
Low
Report
WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager [Yahoo! Finance]
2/2
10:22 pm
vrtx
WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager
Low
Report
WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager
2/2
10:21 pm
vrtx
WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager [Globe and Mail, The (Toronto, Canada)]
Low
Report
WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager [Globe and Mail, The (Toronto, Canada)]
2/2
10:17 pm
vrtx
WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager
Low
Report
WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager
Date
Time
Symbol
Company Name
Action
%Chg
11/3/2025
04:02 pm
vrtx
vertex pharmaceuticals incorporated
BEAT
Report
-0.9%
vertex pharmaceuticals incorporated
8/4/2025
04:01 pm
vrtx
vertex pharmaceuticals incorporated
BEAT
Report
-20.6%
vertex pharmaceuticals incorporated
5/5/2025
04:01 pm
vrtx
vertex pharmaceuticals incorporated
BEAT
Report
-10.0%
vertex pharmaceuticals incorporated
2/10/2025
04:01 pm
vrtx
vertex pharmaceuticals incorporated
BEAT
Report
-3.1%
vertex pharmaceuticals incorporated
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/3
04:09 pm
vrtx
Form 3 VERTEX PHARMACEUTICALS For: Feb 01 Filed by: Bunnage Mark E.
Low
Report
Form 3 VERTEX PHARMACEUTICALS For: Feb 01 Filed by: Bunnage Mark E.
1/26
04:38 pm
vrtx
Form 4 VERTEX PHARMACEUTICALS For: Jan 22 Filed by: WAGNER CHARLES F JR
Low
Report
Form 4 VERTEX PHARMACEUTICALS For: Jan 22 Filed by: WAGNER CHARLES F JR
1/26
04:37 pm
vrtx
Form 4 VERTEX PHARMACEUTICALS For: Jan 22 Filed by: Tatsis Ourania
Low
Report
Form 4 VERTEX PHARMACEUTICALS For: Jan 22 Filed by: Tatsis Ourania
1/26
04:35 pm
vrtx
Form 4 VERTEX PHARMACEUTICALS For: Jan 22 Filed by: Sachdev Amit
Low
Report
Form 4 VERTEX PHARMACEUTICALS For: Jan 22 Filed by: Sachdev Amit
1/26
04:30 pm
vrtx
Form 4 VERTEX PHARMACEUTICALS For: Jan 22 Filed by: McKechnie Duncan
Low
Report
Form 4 VERTEX PHARMACEUTICALS For: Jan 22 Filed by: McKechnie Duncan
1/26
04:28 pm
vrtx
Form 4 VERTEX PHARMACEUTICALS For: Jan 22 Filed by: LEIDEN JEFFREY M
Low
Report
Form 4 VERTEX PHARMACEUTICALS For: Jan 22 Filed by: LEIDEN JEFFREY M
1/26
04:26 pm
vrtx
Form 4 VERTEX PHARMACEUTICALS For: Jan 22 Filed by: Kewalramani Reshma
Low
Report
Form 4 VERTEX PHARMACEUTICALS For: Jan 22 Filed by: Kewalramani Reshma
1/26
04:22 pm
vrtx
Form 4 VERTEX PHARMACEUTICALS For: Jan 22 Filed by: Bozic Carmen
Low
Report
Form 4 VERTEX PHARMACEUTICALS For: Jan 22 Filed by: Bozic Carmen
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/12
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
8.1%
4/1 Form 8-K VERTEX PHARMACEUTICALS For: Apr 01 7.7%
3/4 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $271.00 price target on the stock. 7.6%
7/31 Q2/2019 6/30/2019 EPS 1.260 ZacksConsensus 0.750 ActVsEst 0.510 - Beat 7.6%
3/2 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Argus from $248.00 to $270.00. They now have a "buy" rating on the stock. 5.1%
3/28 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "buy" rating re-affirmed by analysts at Piper Sandler. They now have a $300.00 price target on the stock. 5.0%
10/19 Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia 4.1%
10/21 Form 8-K VERTEX PHARMACEUTICALS For: Oct 21 4.1%
4/6 Form SEC STAFF LETTER VERTEX PHARMACEUTICALS 3.8%
4/15 Form 4 VERTEX PHARMACEUTICALS For: Apr 13 Filed by: Silva Paul M 3.7%
4/1 Form 8-K VERTEX PHARMACEUTICALS For: Apr 01 7.7%
3/4 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $271.00 price target on the stock. 7.6%
7/31 Q2/2019 6/30/2019 EPS 1.260 ZacksConsensus 0.750 ActVsEst 0.510 - Beat 7.6%
3/2 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Argus from $248.00 to $270.00. They now have a "buy" rating on the stock. 5.1%
3/28 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "buy" rating re-affirmed by analysts at Piper Sandler. They now have a $300.00 price target on the stock. 5.0%
10/19 Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia 4.1%
10/21 Form 8-K VERTEX PHARMACEUTICALS For: Oct 21 4.1%
4/6 Form SEC STAFF LETTER VERTEX PHARMACEUTICALS 3.8%
4/15 Form 4 VERTEX PHARMACEUTICALS For: Apr 13 Filed by: Silva Paul M 3.7%
TOP News Decliners
1/30
Vertex Pharmaceuticals Inc (VRTX) Q4 2019 Earnings Call Transcript [The Motley Fool]
-6.8%
4/7 The Vertex Foundation Commits $5 Million to Support Global COVID-19 Pandemic Response -6.2%
3/7 2 Biotech Stocks to Buy as Coronavirus Fears Tank the Market [The Motley Fool] -5.9%
4/28 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating. -5.1%
3/17 Crispr: Beyond Gene-Editing [Seeking Alpha] -5.0%
4/21 Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI® (lumacaftor/ivacaftor) and SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Cystic Fibrosis Patients -4.4%
4/30 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at JMP Securities from $255.00 to $285.00. They now have a "market outperform" rating on the stock. -4.1%
2/26 Form 4 VERTEX PHARMACEUTICALS For: Feb 24 Filed by: WAGNER CHARLES F JR -3.8%
9/4 Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff [The Motley Fool] -3.7%
5/28 Form 4 VERTEX PHARMACEUTICALS For: May 24 Filed by: LEIDEN JEFFREY M -3.6%
4/7 The Vertex Foundation Commits $5 Million to Support Global COVID-19 Pandemic Response -6.2%
3/7 2 Biotech Stocks to Buy as Coronavirus Fears Tank the Market [The Motley Fool] -5.9%
4/28 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating. -5.1%
3/17 Crispr: Beyond Gene-Editing [Seeking Alpha] -5.0%
4/21 Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI® (lumacaftor/ivacaftor) and SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Cystic Fibrosis Patients -4.4%
4/30 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at JMP Securities from $255.00 to $285.00. They now have a "market outperform" rating on the stock. -4.1%
2/26 Form 4 VERTEX PHARMACEUTICALS For: Feb 24 Filed by: WAGNER CHARLES F JR -3.8%
9/4 Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff [The Motley Fool] -3.7%
5/28 Form 4 VERTEX PHARMACEUTICALS For: May 24 Filed by: LEIDEN JEFFREY M -3.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: